JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer

  • 0Clinical College of Central Gynecology and Obstetrics, Tianjin Medical University, Tianjin, 300070, China.
Open Medicine (warsaw, Poland) +

|

September 8, 2025

|

September 8, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Decreased exomiR-188-3p in exosomes shows potential as an early diagnostic and prognostic biomarker for ovarian cancer (OC). Lower levels correlate with advanced disease and poor survival, aiding in early detection and patient management.

Area Of Science

  • Biochemistry
  • Molecular Biology
  • Oncology

Background

  • Exosomal microRNAs (exomiRs) are emerging as promising biomarkers for cancer detection and prognosis.
  • Ovarian cancer (OC) diagnosis and prognosis can be significantly improved with novel biomarkers.
  • Identifying specific exomiRs for OC is crucial for clinical applications.

Purpose Of The Study

  • To identify and validate exomiRs as potential biomarkers for ovarian cancer (OC).
  • To assess the diagnostic and prognostic value of candidate exomiRs in OC patients.
  • To investigate the correlation between exomiR expression and clinicopathological features of OC.

Main Methods

  • Screening of candidate exomiRs using public datasets (GSE235525, GSE239685, GSE216150).
  • Validation of exomiR expression in serum samples from OC patients and cell lines via quantitative PCR (qPCR).
  • Correlation analysis with clinicopathological features, Kaplan-Meier survival analysis, and ROC curve analysis.

Main Results

  • ExomiR-188-3p was significantly downregulated in OC patients and cell lines compared to controls.
  • Lower exomiR-188-3p expression correlated with advanced FIGO stage, lymph node metastasis, and distant metastasis.
  • ExomiR-188-3p demonstrated diagnostic potential (AUC 0.8983) and improved efficacy when combined with CA125 (AUC 0.9323), predicting poor survival.

Conclusions

  • Downregulated exomiR-188-3p serves as a potential early diagnostic biomarker for ovarian cancer.
  • Decreased exomiR-188-3p expression is a significant prognostic indicator for OC patients.
  • ExomiR-188-3p holds promise for improving early detection and patient outcome assessment in OC.

Keywords: